Please use this identifier to cite or link to this item:
Title: Characterization of a novel tumor-suppressor gene PLCδ1 at 3p22 in esophageal squamous cell carcinoma
Authors: Kwong, DL;Srivastava, G;Guan, XY;Qin, YR;Xie, D;Hu, L;Sai, WT;Fu, L
Year: 2007
Publisher: American Association for Cancer Research. The Journal's web site is located at
United States
Description: Correction for this article:
Deletion of 3p is one of the most frequent chromosomal alterations in many solid tumors, including esophageal squamous cell carcinoma (ESCC), suggesting the existence of one or more tumor-suppressor genes at 3p. Recently, our loss of heterozygosity study revealed that 3p22 was frequently deleted in ESCC and a candidate tumor-suppressor gene (TSG), phospholipase C-δ1 (PLCδ1), was identified within the 3p22 region. In this study, absent expression of PLCδ1 was detected in 26 of 50 (52%) primary ESCCs and 4 of 9 (44.4%) ESCC cell lines, which was significantly associated with DNA copy number loss and promoter hypermethylation (P < 0.05). Functional studies showed that PLCδ1 was able to suppress both in vitro and in vivo tumorigenic ability of ESCC cells, including foci formation, colony formation in soft agar, and tumor formation in nude mice. The tumor-suppressive mechanism of PLCδ1 was associated with its role in the cell cycle arrest at the G 1-S checkpoint by up-regulation of p21 and down-regulation of phosphorylated Akt (Ser 473). In addition, down-regulation of PLCδ1 protein was significantly correlated with ESCC metastasis (P = 0.014), which was associated with its function in increasing cell adhesion and inhibiting cell mobility. Taken together, our results suggest that PLCδ1 plays an important suppressive role in the development and progression of ESCC. ©2007 American Association for Cancer Research.
Standard no: Cancer Research, 2007, v. 67 n. 22, p. 10720-10726
Appears in Collections:Department of Anatomy

Files in This Item:
Click on the URI links for accessing contents.

Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.